Treatment response and tolerability of intralesional quadrivalent versus bivalent human papillomavirus vaccine for recalcitrant warts: A randomized controlled trial
Second Author's Department
Biotechnology Program
Document Type
Research Article
Publication Title
Journal of the American Academy of Dermatology
Publication Date
11-1-2023
doi
10.1016/j.jaad.2023.06.042
First Page
1051
Last Page
1052
Recommended Citation
APA Citation
Nofal, A.
Nofal, H.
Alwirshiffani, E.
&
ElGhareeb, M.
(2023). Treatment response and tolerability of intralesional quadrivalent versus bivalent human papillomavirus vaccine for recalcitrant warts: A randomized controlled trial. Journal of the American Academy of Dermatology, 89(5), 1051–1052.
https://doi.org/10.1016/j.jaad.2023.06.042
MLA Citation
Nofal, Ahmad, et al.
"Treatment response and tolerability of intralesional quadrivalent versus bivalent human papillomavirus vaccine for recalcitrant warts: A randomized controlled trial." Journal of the American Academy of Dermatology, vol. 89, no. 5, 2023, pp. 1051–1052.
https://doi.org/10.1016/j.jaad.2023.06.042